Silverarc Capital Management, LLC Mereo Biopharma Group PLC Transaction History

Silverarc Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 25, 2022	SELL	$0.33 - $1.69 $26,175 - $134,050	-79,320 Reduced 33.68%	156,195 $175,000
Q1 2022 May 13, 2022	BUY	$1.04 - $1.7 $2,425 - $3,964	2,332 Added 1.0%	235,515 $264,000
Q4 2021 Feb 14, 2022	SELL	$1.51 - $2.59 $200,041 - $343,118	-132,478 Reduced 36.23%	233,183 $373,000
Q3 2021 Nov 15, 2021	SELL	$2.2 - $3.17 $88,462 - $127,465	-40,210 Reduced 9.91%	365,661 $885,000
Q2 2021 Aug 16, 2021	BUY	$2.94 - $4.08 $678,760 - $941,953	230,871 Added 131.93%	405,871 $1.29 Million
Q1 2021 May 18, 2021	SELL	$2.6 - $4.43 $273,000 - $465,149	-105,000 Reduced 37.5%	175,000 $590,000
Q4 2020 Feb 16, 2021	BUY	$1.95 - $3.6 $546,000 - $1.01 Million	280,000 New	280,000 $1 Million

107M

209K

479K

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $437M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.